| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | JANX | Common Stock | Other | $0 | -439K | -10% | $0.00 | 3.95M | Feb 29, 2024 | Direct | F1, F2 |
| transaction | JANX | Common Stock | Other | $0 | +11.4K | $0.00 | 11.4K | Feb 29, 2024 | By Avalon Ventures XI GP LLC | F3, F4 | |
| transaction | JANX | Common Stock | Other | $0 | -11.4K | -100% | $0.00* | 0 | Feb 29, 2024 | By Avalon Ventures XI GP LLC | F4, F5 |
| transaction | JANX | Common Stock | Other | $0 | -448K | -10% | $0.00 | 4.03M | Feb 29, 2024 | By Avalon BioVentures SPV I, LP | F6, F7 |
| transaction | JANX | Common Stock | Other | $0 | +31.5K | $0.00 | 31.5K | Feb 29, 2024 | By ABV SPV I GP LLC | F8, F9 | |
| transaction | JANX | Common Stock | Other | $0 | -31.5K | -100% | $0.00* | 0 | Feb 29, 2024 | By ABV SPV I GP LLC | F9, F10 |
| transaction | JANX | Common Stock | Other | $0 | -85K | -10% | $0.00 | 765K | Feb 29, 2024 | By Avalon BioVentures I, LP | F11, F12 |
| transaction | JANX | Common Stock | Other | $0 | +1.7K | $0.00 | 1.7K | Feb 29, 2024 | By Avalon BioVentures GP LLC | F13, F14 | |
| transaction | JANX | Common Stock | Other | $0 | -1.7K | -100% | $0.00* | 0 | Feb 29, 2024 | By Avalon BioVentures GP LLC | F14, F15 |
| Id | Content |
|---|---|
| F1 | Represents a pro-rata, in-kind distribution, and not a purchase or sale of securities, by Avalon Ventures XI LP (Avalon Ventures) to its general partner and limited partners without additional consideration. |
| F2 | The shares are held directly by Avalon Ventures. Avalon Ventures XI GP, LLC (Avalon XI GP) is the general partner of Avalon Ventures and may be deemed to beneficially own the shares held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| F3 | Represents receipt of shares in the distribution in kind described in footnote (1). |
| F4 | The shares are held directly by Avalon XI GP. Avalon XI GP is the general partner of Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| F5 | Represents a pro rata, in-kind distribution, and not a purchase or sale of securities, by Avalon XI GP to its members without additional consideration. |
| F6 | Represents a pro rata, in-kind distribution, and not a purchase or sale of securities by Avalon BioVentures SPV I, LP (ABV SPV) to its general partner and limited partners without additional consideration. |
| F7 | The shares are directly held by ABV SPV. ABV SPV I GP LLC (ABV SPV GP) is the general partner of ABV SPV and may be deemed to beneficially own the shares held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| F8 | Represents receipt of shares in the distribution in kind described in footnote (6). |
| F9 | The shares are held directly by ABV SPV GP. ABV SPV GP is the general partner of ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| F10 | Represents a pro rata, in-kind distribution, and not a purchase or sale of securities, by ABV SPV GP to its members without additional consideration. |
| F11 | Represents a pro-rata, in kind distribution, and not a purchase or sale of securities, by Avalon BioVentures I, LP (ABV I) to its general partner and limited partners without additional consideration. |
| F12 | The shares are held directly by ABV I. Avalon BioVentures GP, LLC (ABV GP) is the general partner of ABV I and may be deemed to beneficially own the shares held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| F13 | Represents receipt of shares in the distribution in kind described in footnote (11). |
| F14 | The shares are held directly by ABV GP. ABV GP is the general partner of ABV I. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| F15 | Represents a pro rata, in-kind distribution, and not a purchase or sale of securities, by ABV GP to its members without additional consideration. |